Performance of Hepatitis C Virus (HCV) Core Antigen Assay in the Diagnosis of Recently Acquired HCV Infection among High-Risk Populations

Hsin-Yun Sun,Wang-Da Liu,Chih-Wen Wang,Yu-Ju Wei,Kuan-Yin Lin,Yu-Shan Huang,Li-Hsin Su,Yi-Ting Chen,Wen-Chun Liu,Yi-Chin Su,Yea-Wen Chen,Yu-Chung Chuang,Po-Liang Lu,Chien-Ching Hung,Ming-Lung Yu

DOI: https://doi.org/10.1128/spectrum.00345-22

IF: 3.7

2022-06-29

Microbiology Spectrum

Abstract:The HCV core antigen assay has a high specificity of 99.4% and negative predictive value of 99.5% but a lower sensitivity of 87.1% and positive predictive value of 85.7% in the diagnosis of recently acquired HCV infection in high-risk populations. Our findings are informative for many countries confronted with limited resources to timely identify acute HCV infections and provide effective direct-acting antivirals to halt onward transmission.

microbiology

What problem does this paper attempt to address?

The paper primarily explores the performance of Hepatitis C Virus (HCV) core antigen (HCVcAg) testing in diagnosing recently acquired HCV infections, particularly among high-risk populations, including sexually active men who have sex with men (MSM) living with people living with HIV (PLWH) and HIV-negative MSM.

The main findings of the study are as follows:
1. In high-risk groups, the specificity of HCVcAg testing is 99.4%, with a negative predictive value of 99.5%. However, the sensitivity is relatively low at 87.1%, and the positive predictive value is also relatively low at 85.7%.
2. The study found that samples are more likely to test positive for HCVcAg when the HCV RNA load is greater than 3000 IU/mL.
3. The mean HCV RNA load in blood samples is significantly higher in samples that are positive for both HCV RNA and HCVcAg compared to those that are only HCV RNA positive.
4. The study also analyzed blood samples collected at different time points (such as at enrollment and during follow-up) to evaluate the performance of HCVcAg testing and found similar performance.

In conclusion, HCVcAg testing has high specificity and negative predictive value in diagnosing recently acquired HCV infections, but its sensitivity and positive predictive value are lower in cases of low HCV RNA load. This suggests that HCVcAg testing can be a cost-effective screening tool, especially in resource-limited settings where repeated testing of high-risk populations is needed. However, its performance is affected in cases of low HCV RNA load, which may be an area for future research.